Skip to main content

RUBY-3 Clinical Study

RUBY-3 is a clinical study for people with IgA nephropathy (IgAN), lupus nephritis (lupus-related kidney disease), or primary membranous nephropathy.

RUBY-3 is a phase 1/2 clinical study for patients whose autoimmune kidney disease is not well controlled with their current medication(s). RUBY-3 is exploring the safety and potential effectiveness of an investigational drug called povetacicept (ALPN-303) for people with IgAN, lupus nephritis, or primary membranous nephropathy.

All participants who enroll in RUBY-3 will receive study treatment with povetacicept given as an injection under the skin. There is no placebo group in RUBY-3.

learn more about povetacicept

IgA Nephropathy

PHASE 1/2

Participants must meet the following requirements:

  • 18 years of age or older
  • have IgAN that is confirmed by a biopsy
  • currently have active IgAN despite receiving standard study treatment(s)

Additional requirements apply. Our study doctors can help determine if you qualify.

learn more

Lupus Nephritis

PHASE 1/2

Participants must meet the following requirements:

  • 18 years of age or older
  • have lupus nephritis that is confirmed by a biopsy
  • currently have active lupus nephritis despite receiving standard study treatment(s)

Additional requirements apply. Our study doctors can help determine if you qualify.

learn more

Primary Membranous Nephropathy

PHASE 1/2

Participants must meet the following requirements:

  • 18 years of age or older
  • have primary membranous nephropathy that is confirmed by a biopsy
  • currently have active membranous nephropathy despite receiving standard study treatment(s)

Additional requirements apply. Our study doctors can help determine if you qualify.

learn more

Frequently Asked Questions

What is the study drug, povetacicept?

What is a clinical study?
learn more about clinical studies

Why join a clinical study?